Ventura, I.; Salcedo, N.P.; Pérez-Bermejo, M.; Pérez-Murillo, J.; Tejeda-Adell, M.; Tomás-Aguirre, F.; Legidos-GarcÃa, M.E.; Murillo-Llorente, M.T.
Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review. Int. J. Mol. Sci. 2025, 26, 1908.
https://doi.org/10.3390/ijms26051908
AMA Style
Ventura I, Salcedo NP, Pérez-Bermejo M, Pérez-Murillo J, Tejeda-Adell M, Tomás-Aguirre F, Legidos-GarcÃa ME, Murillo-Llorente MT.
Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review. International Journal of Molecular Sciences. 2025; 26(5):1908.
https://doi.org/10.3390/ijms26051908
Chicago/Turabian Style
Ventura, Ignacio, Nerea Pinilla Salcedo, Marcelino Pérez-Bermejo, Javier Pérez-Murillo, Manuel Tejeda-Adell, Francisco Tomás-Aguirre, MarÃa Ester Legidos-GarcÃa, and MarÃa Teresa Murillo-Llorente.
2025. "Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review" International Journal of Molecular Sciences 26, no. 5: 1908.
https://doi.org/10.3390/ijms26051908
APA Style
Ventura, I., Salcedo, N. P., Pérez-Bermejo, M., Pérez-Murillo, J., Tejeda-Adell, M., Tomás-Aguirre, F., Legidos-GarcÃa, M. E., & Murillo-Llorente, M. T.
(2025). Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review. International Journal of Molecular Sciences, 26(5), 1908.
https://doi.org/10.3390/ijms26051908
